ImmuPharma plc (LON:IMM – Get Free Report) traded down 11.6% on Thursday . The company traded as low as GBX 2.50 ($0.03) and last traded at GBX 2.57 ($0.03). 6,519,809 shares traded hands during trading, a decline of 43% from the average session volume of 11,538,609 shares. The stock had previously closed at GBX 2.90 ($0.04).
ImmuPharma Stock Performance
The company has a fifty day simple moving average of GBX 3.92 and a two-hundred day simple moving average of GBX 2.48. The firm has a market capitalization of £10.78 million, a PE ratio of -4.39 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- How to Invest in Blue Chip Stocks
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- What Are Earnings Reports?
- The 3 Most Talked About Investments on WallStreetBets Right Now
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
